> Co-administration of isavuconazole with the strong CYP3A4 /5 inhibitor KETOCONAZOLE is contraindicated , since th is medicinal product can significantly increase plasma concentrations of isavuconazole (see sections 4.3 and 4.5).  For the strong CYP3A4 inhibitor LOPINAVIR/RITONAVIR, a two -fold increase in isavuconazole exposure was observed. For other strong CYP3A4 inhibitors, such as CLARITHROMYCIN, INDINAVIR and SAQUINAVIR , a 6
> Co-administration of isavuconazole with potent CYP3A4 /5 inducers such as rifampicin,  RIFABUTIN, CARBAMAZEPINE, long -acting barbiturates (e.g. , PHENOBARBITAL), PHENYTOIN and St. John’s wort, or with moderate CYP3A4/5  inducers such as EFAVIRENZ, NAFCILLIN and ETRAVIRINE,  is contraindicated, since these medicinal products can significantly decrease plasma concentrations of isavuconazole (see section 4.3) .
> Co-administration with mild CYP3A4/5  inducers such as APREPITANT , PREDNISONE and PIOGLITAZONE, may result in mild to moderate decreases of isavuconazole plasma levels ; co-administration with mild CYP3A4 /5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.4) .
> Co-administration with high -dose RITONAVIR ( >200 mg twice daily) is contraindicated, as at high dose s RITONAVIR may induce CYP3A4/5  and decrease isavuconazole plasma concentrations (see section 4.3) .
> Co-administered  medicinal product by therapeutic area Effects on drug  concentrations /  Geometric Mean  Change (%) in AUC,  Cmax (Mode of action)  Recommendation  concerning  co-administration   Anticonvulsants  CARBAMAZEPINE, PHENOBARBITAL and PHENYTOIN (strong CYP3A4/5 inducers)  Isavuconazole concentrations may decrease (CYP3A induction by CARBAMAZEPINE, PHENYTOIN and long- acting barbiturates such as PHENOBARBITAL).  The concomitant administration of isavuconazole and CARBAMAZEPINE, PHENYTOIN and long- acting barbiturates such as PHENOBARBITAL is contraindicated.  Antibacterials    Rifampicin  (strong CYP3A4/5 inducer) Isavuconazole  : AUC tau : ↓ 90%  Cmax : ↓ 75% 
> (CYP3A4/5 induction)  The concomitant administration of isavuconazole and rifampicin is contraindicated.  RIFABUTIN  (strong CYP3A4/5 inducer) Not studied.  Isavuconazole concentrations may significantly decrease.
> (CYP3A4/5 induction)  The concomitant administration of isavuconazole and RIFABUTIN is contraindicated. NAFCILLIN  (moderate CY3A4/5 inducer)  Not studied.  Isavuconazole concentrations  may significantly decrease.   (CYP3A4/5 induction)  The concomitant administration of isavuconazole and NAFCILLIN is contraindicated. CLARITHROMYCIN  (strong CYP3A4/5 inhibitor)  Not studied.  Isavuconazole concentrations may increase. 
> (CYP3A4/5 inhibition)  The concomitant administration of isavuconazole and KETOCONAZOLE is contraindicated.  Herbal medicines  St John’s wort  (strong CYP3A4/5 inducer) Not studied.  Isavuconazole concentrations may  significantly decrease . The concomitant administration of isavuconazole and St John’s wort is contraindicated.  8
> (CYP3A4/5 induction)  Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.
 OPIOIDS  Short -acting opiates (alfentanyl, FENTANYL)  (CYP3A4/5 substrate)  Not studied.  Short -acting opiate concentrations may increase. 
> (CYP2B6 induction)  No isavuconazole dose adjustment necessary.  METHADONE: no dose adjustment required.  Anti-cancer  Vinca alkaloids (VINCRISTINE, VINBLASTINE)  (P-gp substrates)  Not studied.  Vinca alkaloid concentrations may increase. 
> CYCLOPHOSPHAMIDE  (CYP2B6 , CYP3A4  substrate)  Not studied.  Active metabolites of CYCLOPHOSPHAMIDE may increase or decrease. 
> (CYP2B6 induction, CYP3A4 inhibition ) No isavuconazole dose adjustment necessary.  CYCLOPHOSPHAMIDE: careful monitoring for any occurrence of lack of efficacy  or increased toxicity , and dose adjustment  if required.  METHOTREXATE  (BCRP, OAT1, OAT3 substrate)  METHOTREXATE:  AUC inf: ↓ 3%  Cmax: ↓ 11% 
> (Mechanism unknown)  No isavuconazole dose adjustment necessary.  METHOTREXATE: no dose adjustment required.  Other anticancer agents (DAUNORUBICIN, DOXORUBICIN, IMATINIB, IRINOTECAN, LAPATINIB, MITOXANTRONE, TOPOTECAN)  (BCRP substrates)  Not studied.  DAUNORUBICIN, DOXORUBICIN, IMATINIB, IRINOTECAN, LAPATINIB, MITOXANTRONE, TOPOTECAN concentrations may increase.
> (BCRP inhibition)  No isavuconazole dose adjustment necessary.  DAUNORUBICIN, DOXORUBICIN, IMATINIB, IRINOTECAN, LAPATINIB, MITOXANTRONE or TOPOTECAN: careful monitoring for any occurrence of drug toxicity, and dose reduction if required.  Antiemetics  APREPITANT  (mild CYP3A4/5 inducer)  Not studied.  Isavuconazole concentrations may decrease. 
> (CYP3A4/5 induction)  Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.
 Antidiabetics  METFORMIN  (OCT1, OCT2 and MATE1 substrate)  METFORMIN:  AUC inf: ↑ 52%  Cmax: ↑ 23% 
> (OCT2 inhibition)  No isavuconazole dose adjustment necessary.  METFORMIN:  dose reduction may be required.  REPAGLINIDE  (CYP2C8 and OATP1B1 substrate)  REPAGLINIDE:  AUC inf: ↓  8%  Cmax: ↓ 14%  No isavuconazole dose adjustment necessary.  REPAGLINIDE: no dose adjustment required.  PIOGLITAZONE  (mild CYP3A4/5 inducer)  Not studied.  Isavuconazole concentrations may decrease. 
> (CYP3A4/5 induction)  Co-administration should be avoided unless the potential benefit is considered to outweigh the risk.  Anticoagulants  DABIGATRAN ETEXILATE  (P-gp substrate)  Not studied.  DABIGATRAN ETEXILATE concentrations may increase. 
> RITONAVIR (at doses >200 mg every 12 hours)  (strong CYP3A4/5 inducer)  Not studied.  RITONAVIR at high doses may significantly decrease isavuconazole concentrations. 
> (CYP3A4/5 induction)  The concomitant administration of isavuconazole and high doses of RITONAVIR ( >200 mg every 12 hours) is contraindicated.  Efaviren z  (CYP3A4/5 moderate inducer and CYP2B6 substrate)  Not studied.  EFAVIRENZ concentrations may decrease. 
> (CYP3A4/5 induction)  The concomitant administration of isavuconazole and EFAVIRENZ is contraindicated.  ETRAVIRINE  (moderate CYP3A4 /5 inducer)  Not studied.  Isavuconazole concentrations may significantly decrease. 
> (CYP3A4/5 induction)  The concomitant administration of isavuconazole and ETRAVIRINE is contraindicated.  INDINAVIR  (CYP3A4/5 strong inhibitor and substrate)  INDINAVIR:b) AUC inf: ↓ 36%  Cmax: ↓ 52% 
> (CYP3A4/5 inhibition)  No isavuconazole dose adjustment necessary ; caution is advised as adverse drug reactions may increase.  INDINAVIR: careful monitoring for any occurrence of lack of anti -viral efficacy, and dose increase if required.  11
> SAQUINAVIR  (strong CYP3A4 inhibitor)  Not studied.  SAQUINAVIR concentrations may decrease (as observed with LOPINAVIR/RITONAVIR) or increase .
> (CYP3A4/5 inhibition)  No isavuconazole dose adjustment necessary ; caution is advised as adverse drug reactions may increase.  SAQUINAVIR: careful monitoring for any occurrence of drug toxicity and /or lack of anti -viral efficacy, and dose adjustment if required  Other PROTEASE INHIBITORS (e.g.  FOSAMPRENAVIR ) (CYP3A4/5 strong or moderate inhibitors and substrates)  Not studied.  Protease inhibitor concentrations may decrease (as observed with LOPINAVIR/RITONAVIR) or increase . 
> (CYP3A4/ 5 inhibition)  No isavuconazole  dose adjustment necessary.  PROTEASE INHIBITORS: careful monitoring for any occurrence of drug toxicity and /or lack of anti -viral efficacy, and dose adjustment if required.  Other NNRTI (e.g.  NEVIRAPINE ) (CYP3A4/5 and 2B6 inducers and substrates)  Not studied.  NNRTI concentrations may decrease (CYP2B6 induction by isavuconazole) or increase. 
> H ↑ ) OMEPRAZOLE:  AUC inf: ↓ 11%  Cmax: ↓ 23%  No isavuconazole  dose adjustment necessary.  OMEPRAZOLE: no dose adjustment required.  Lipid -lowering agents  ATORVASTATIN and other statins (CYP3A4 substrates e.g.,  SIMVASTATIN, LOVASTATIN, ROSUVASTATIN)  (CYP3A4/5 and/or BCRP substrates))  ATORVASTATIN :  AUC inf: ↑ 37%  Cmax: ↑ 3%  Other statins were not studied . Statins concentrations may increase. 
> (CYP3A4 inhibition) No isavuconazole dose adjustment necessary.  MIDAZOLAM: careful monitoring of clinical signs and symptoms recommended, and dose reduction if required.  Antigout agent  COLCHICINE  (P-gp substrate)  Not studied.  COLCHICINE concentrations may increase.
> (CYP2B6 induction)  No isavuconazole dose adjustment necessary.  BUPROPION: dose increase if required. NNRTI, non -nucleoside reverse -transcriptase inhibitor; P -gp, P -glycoprotein.  a) % decrease of the mean trough level values b) INDINAVIR was only studied after a single dose of 400 mg isavuconazole. AUC inf = area under the plasma concentration -time profiles extrapolated to infinity; AUC tau = area under the plasma concentration-time profiles during the 24 h interval at steady state; C max = peak plasma concentration; Cmin,ss = trough levels at steady  state. 
